About CSL Behring
The CSL Behring Mission
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture, and market life-saving biotherapies used to treat serious and rare conditions, including such bleeding disorders as hemophilia and von Willebrand disease.
Our commitment to saving lives and improving the lives of people with serious and rare conditions is evident in everything we do. We are focused first and foremost on fulfilling our customers’ needs, whether by manufacturing and marketing safe and effective products or by researching and developing innovative biotherapies.
What are Biotherapies
Biotherapies differ from chemical-derived pharmaceuticals in many ways. Mainly, biotherapies are not derived from chemicals, but are derived from human plasma or produced as their recombinant equivalents. Biotherapies undergo rigorous safety controls and inspections throughout every step of a yearlong manufacturing process from the collection of plasma to the finished product.
Our products are produced in accordance with US safety and quality standards. The company also operates CSL (formerly ZLB) Plasma, which includes the largest plasma collection networks in the United States.
CSL Behring employs more than 11,000 employees worldwide who are passionate about safety, quality, and the customers we serve. Our extensive research and development and range of support services demonstrate our ongoing commitment to the people who count on our products.
History of Innovation
CSL is a global specialty biopharmaceutical company that aims to identify, develop, and market biotherapeutic products that save lives by preventing or treating serious medical conditions.
We are committed to significantly investing in future research and development (R&D) in
- Plasma replacement therapies
- Therapeutic proteins
- CSL Behring
- CSL Plasma
- CSL Biotherapies
- CSL Bioplasma
These 4 businesses have a combined heritage of outstanding contributions to medicine and human health, with more than 100 years of experience in the development and manufacture of vaccines and plasma protein biotherapies.
Our strong commitment to funding research and development of protein-based medicines for unmet medical needs underpins our continued growth.
To learn more about CSL’s longstanding commitment to R&D, please visit CSL-Behring-US.com.